Pulse Biosciences, Inc. PLSE

Company Overview

Pulse Biosciences, Inc. is a U.S.-based medical technology company focused on developing and commercializing therapeutic applications that use ultra-short pulsed electric fields, marketed under its proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology platform. The company operates within the medical device and bioelectric medicine industries, with primary emphasis on electrophysiology, surgical oncology, dermatology, and soft tissue treatment applications. Pulse Biosciences’ technology is designed to deliver non-thermal electrical energy in nanosecond durations to selectively affect cellular structures while minimizing collateral tissue damage compared with some conventional thermal-based ablation methods.

The company’s principal revenue drivers remain tied to the development, regulatory advancement, and commercialization of its nsPFA systems and associated disposable devices. Pulse Biosciences has historically focused on investigational and early commercial opportunities involving cardiac ablation and tumor treatment technologies. The company was founded in 2014 and is headquartered in Hayward, California. Its evolution has centered on expanding applications for pulsed electric field technologies across multiple medical specialties, with strategic emphasis on minimally invasive procedures and next-generation energy delivery systems.